Ajuts a la recerca

Innovative Medicines Initiative 8th Call

Organisme

IMI projects receive funding from the European Commissions' Seventh Framework Programme for Research, which is matched by mostly in-kind contributions (consisting of research activities and other resources), provided by the research-based pharmaceutical companies that are members of EFPIA, the European Federation of Pharmaceutical Industries and Associations.

Objecte

The aim of IMI is to support pre-competitive pharmaceutical research and development to foster the development of safe and more effective medicines for patients throughremoving identified bottlenecks in the drug development process and enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic hightechnology sector.
 

The IMI 8th Call 2012 for proposals will have 2 topics covering the following key research priorities:

• Antimicrobial resistance (two topics)
• European induced pluripotent stem cell bank
• Developing an aetiology-based taxonomy of human disease
   

Sol·licitants

IMI launches a new set of research and/or training projects every year, in order to support prospective, pre-competitive pharmaceutical research and development. Project participants are recruited through open and competitive Calls for research proposals. The selection of the winning proposals is based on independent peer review and concluded by a Grant Agreement and Project Agreement.

Descripció

Topics under consideration under the IMI programme Combating Antibiotic Resistance: New Drugs for Bad Bugs (ND4BB)*

Topic 1C: Innovative Trial Design & Clinical Development (work package 6 of Topic 1)

Topic 3: Discovery and development of new drugs combating Gram – negative infections
 

*ND4BB (‘New Drugs for Bad Bugs’) represents a core element of the Action plan against the rising threats from Antimicrobial Resistance adopted by the European Commission as an answer to the Council Conclusions and the European Parliament resolution to establish an EU-wide plan to combat antimicrobial resistance. The ND4BB programme started in IMI’s 6th Call launched in May 2012 with two topics, and further topics are under consideration.
 

Other topics under consideration
 

• Developing an aetiology-based taxonomy of human disease
   
• European induced pluripotent stem cell bank

Funding

For research and technological development activities, up to 75% of the eligible costs and for other activities (including management and training activities) up to 100% of the eligible costs charged to the project are eligible for funding. For the indirect costs (overheads), the legal entities eligible for funding may opt for one of the following indirect costs methods: the actual indirect costs; or the simplified method which is a modality of the actual indirect costs for organisations which do not aggregate their indirect costs at a detailed level, but can aggregate them at the level of the legal entity; or a flat rate of 20% of total eligible direct costs (excluding subcontracting costs and the costs of resources made available by third parties which are not used on the premises of the beneficiary).

Termini oficial

The Innovative Medicine Initiative Joint Undertaking (IMI JU) has published on its web the information necessary to submit an Expression of Interest in response to IMI 8th Call 2012

Official deadline for submission of EoIs: 28 February 2013

Termini IISPV

Cal comunicar abans del 31 de gener de 2013 que es vol participar a la convocatòria, enviant un e-mail a convocatories@iispv.cat . Termini: 15 de febrer de 2013

Pujar